Please login to the form below
Janssen
This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.
Janssen’s Stelara approved by FDA for psoriatic arthritis in paediatric patients
Janssen – a pharmaceutical arm of Johnson &Johnson – has announced that Stelara (ustekinumab) has been approved by the US Food and Drug Administration (FDA) for the treatment of paediatric patients aged six ... Commenting on the approval, Jennifer
Latest news
-
Janssen announces positive results supporting Rybrevant and lazertinib combination treatment for NSCLC
The Janssen Pharmaceutical Companies of Johnson &Johnson has announced new data from a phase 1b/2 study, supporting the safety and efficacy of the combination treatment of Rybrevant (amivantamab-vmjw) and
-
FDA limits use of Janssen’s COVID-19 vaccine
Authorisation of Janssen COVID-19 vaccine restricted among certain people following analysis and evaluation. ... The Janssen COVID-19 vaccine was authorised for emergency use in February 2021.
-
Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara
Amgen has announced preliminary results from a phase 3 study evaluating the efficacy and safety of its drug candidate ABP 654 compared to Janssen’s Stelara in adult patients with moderate
-
Janssen shares new clinical trial data on its psoriasis treatment Tremfya
The Janssen Pharmaceutical Companies of Johnson &Johnson has announced Tremfya (guselkumab) demonstrated consistent and durable skin clearance. ... Despite effective medical treatments for the disease, people living with psoriasis can experience
-
Verily Life Science signs new contract with Oncimmune for long COVID study
while working with Janssen to understand the impact COVID-19 can have on a patient’s immune system immediately after receiving a positive test result.
More from news
Approximately 153 fully matching, plus 419 partially matching documents found.
Latest Intelligence
-
My journey advancing the science in pulmonary hypertension
It’s exactly how we are at Janssen now, and I am thankful to have a team dedicated to driving the science forwards. ... Neil Davie is Head of Late Development, Cardiovascular, Metabolism &Pulmonary Hypertension at the Janssen Pharmaceutical Companies
-
Paving the way for representation in clinical trials
Lee-Ann Farrell comments: “I’m committed to championing all DE&I efforts throughout Janssen. ... References are available on request. This article has been commissioned by, and developed by, Janssen-Cilag Ltd.
-
Are healthcare brands finally wising up to the power of creative-led communications?
And the list goes on. So it seems, encouragingly, that health and pharma brands – from Pfizer to Teva and Roche Genentech to Janssen – seem to finally be recognising the power of
-
Understanding the ‘real world’ starts and ends with the patient
For the past 20 years, true understanding of the patient experience has been the turnkey for R&D for therapies in pulmonary arterial hypertension (PAH) at Janssen Pulmonary Hypertension (following the ... PAH treatment strategies or interventions, an
-
Unlocking the potential of precision medicine in oncology
Joaquín Casariego García-Lubén talks to PME about how Janssen is driven by the premise of providing personalised treatment solutions in cancer care. ... Joaquín Casariego García-Lubén is EMEA Therapeutic Area Lead Oncology, The Janssen
More from intelligence
Approximately 5 fully matching, plus 56 partially matching documents found.
Latest appointments
-
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
Prior to Genmab, Ahmadi worked as head of experimental medicine and early development oncology at Janssen.
-
Ex-J&J exec Denice Torres joins bluebird bio’s board
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at Johnson &Johnson and Janssen.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Mundipharma appoints Dr Alberto Martinez as president and CEO
Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.
More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.
Latest from PMHub
-
The Difference Collective
Copywriting. AKLRD | A Life in a Day | Allergan | Amgen | Arquer Diagnostics | Bleepa | Boehringer Ingelheim | Galapagos | Inivata | Janssen | Kantar | Maxwellia | Macmillan | Mundipharma | Norgine | Novo Nordisk | Pfizer | Roche | Sanofi | Santen |
-
VISFO invests in a new brand as it continues to grow its client base in the US and Europe
Working with global pharma clients such as Takeda, GSK, Janssen and Abbvie, the consultancy is on a trajectory for growth and has doubled in size due to its commitment to technology,
-
What does the future hold for Light-chain Amyloidosis?
Recently, Darzalex (daratumumab), a monoclonal antibody developed by Genmab and Janssen, that has been available for the management of patients with multiple myeloma across Europe for 5 years, was granted accelerated
-
OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
READ MORE ABOUT OUR WINNING PROJECT WITH WITH JANSSEN BELOW:. The Immunology Training Summit (ITS) 2020 with the Janssen EMEA Immunology team took a week-long face-to-face meeting for ... Strikingly this format is now considered best practice in
-
Mednet Group
Clinigen. Crohns and Colitis Department for International Development. Eisai. Gilead. Janssen.
More from PMHub
Approximately 5 fully matching, plus 31 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- Sanofi halts recruitment for trials assessing MS treatment
- bluebird bio reveals plans to launch two gene therapies
- ONS data reveals significant decrease in COVID-19 antibodies
- UK government’s ‘science superpower’ ambitions to fail without clear plan, Lords committee warns
- How the Royal Society’s EiR programme can help to drive UK innovation
- Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer
- Environment: where does the pharmaceutical industry stand?
- Moderna’s Omicron booster receives MHRA approval
- Lack of evidence for AstraZeneca’s COVID-19 vaccine says UK Department of Health
- NHS England outlines measures to boost capacity ahead of substantial winter pressures
- New research shows drug candidate may effectively treat antibiotic-resistant bacteria
- Sanofi and NIHR enrol first patient in immunisation study for RSV in infants
- AstraZeneca and Daiichi Sankyo receive FDA approval for lung cancer drug
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- FDA approves Incyte’s Pemazyre as first targeted drug for bile duct cancer
- WHO, UNICEF and UNAIDS launch global alliance to end AIDS in children by 2030
- Creating content to trigger behaviour change
- Strategic commitment
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Environment: where does the pharmaceutical industry stand?
- ...
- The communication challenge of helping he next generation to be healthier
- As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
- Are we losing sight of what the democratisation of healthcare really looks like?
- We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...
